Semaglutide Treatment in Type 1 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Obesity in DiabetesObesity/TherapyType 1 Diabetes Mellitus (T1DM)Insulin Sensitivity/ResistanceSemaglutideLipidomicsMetabolomicsWeight LossGlycemic Control for Diabetes Mellitus
Interventions
DRUG

Semaglutide 2.4mg

The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator

DRUG

Semaglutide placebo

Visually identical and same label as the active comparator intervention

Trial Locations (1)

3400

Nordsjaellands Hospital, Hillerød

All Listed Sponsors
collaborator

Steno Diabetes Center Copenhagen

OTHER

collaborator

Steno Diabetes Center Odense

OTHER

collaborator

Zealand University Hospital

OTHER

collaborator

Steno Diabetes Center Aarhus (SDCA), Aarhus University Hospital

UNKNOWN

lead

Nordsjaellands Hospital

OTHER